<body style="display:table; border-collapse:separate; border-spacing:10px;"><div class="separation" id="current" style="display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;"><table class="info">
<tr>
<th nowrap="">ClinicalTrials Identifier:</th><td>NCT00000193</td>
</tr>
<tr>
<th>Updated:</th><td>2013_09_26</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Neurobiology of Opioid Dependence: 2 - 2</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>Neurobiology of Opioid Dependence: 2</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td class="bigdent" colspan="2">
<p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td class="bigdent" colspan="2">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 2</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Double Blind</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: Behavioral, subjective, measures of naloxone-preci</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: Phsyiological, neuroendocrine measures of naloxone</td>
</tr>
<tr>
<th>Condition</th><td>
         Opioid-Related Disorders
      </td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Gamma hydroxybutyric</div>
<p></p>
</td>
</tr>
<tr>
<th>Reference</th><td>
<div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div>
<div>MEDLINE: </div>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>Withdrawn</td>
</tr>
<tr>
<th>Start date</th><td>
         1993-01
      </td>
</tr>
<tr>
<th>Last follow-up date</th><td>
         1998-01
      
      (Actual)
  </td>
</tr>
<tr>
<th>Primary completion date</th><td>
         1998-01
      
      (Actual)
  </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td class="bigdent" colspan="2">
<p>Please contact site for information.</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Male
         </td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Yale University</td>
</tr>
<tr>
<th>Organization study ID</th><td>NIDA-00191-2</td>
</tr>
<tr>
<th>Secondary ID</th><td>K20DA000191
      (US NIH Grant Number)
    </td>
</tr>
<tr>
<th>Secondary ID</th><td>
            K20-00191-2
         </td>
</tr>
<tr>
<th>Sponsor</th><td>
               Yale University
            </td>
</tr>
<tr>
<th>Collaborator</th><td>
               National Institute on Drug Abuse (NIDA)
            </td>
</tr>
<tr>
<th>Collaborator</th><td>
               Yale University
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United States: Federal Government
         </td>
</tr>
</table></div><div class="separation" id="past" style="display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;"><html><body><span><table class="info"><tr><th nowrap="">ClinicalTrials Identifier:</th><td>NCT00000193</td></tr><tr><th>Updated:</th><td>20<del style="background:#ffe6e6;">05_12_08</del><ins style="background:#e6ffe6;">13_09_26</ins><span></span></td></tr><tr><th class="section" colspan="2"><h2>Descriptive Information</h2></th></tr><tr><th>Brief title</th><td><p>Neurobiology of Opioid Dependence: 2 - 2</p></td></tr><tr><th>Official title</th><td><p>Neurobiology of Opioid Dependence: 2</p></td></tr><tr><th>Brief summary</th></tr><tr><td class="bigdent" colspan="2"><p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p></td></tr><tr><th>Detailed description</th></tr><tr><td class="bigdent" colspan="2"><p></p></td></tr><tr><th>Phase</th><td>Phase 2</td></tr><tr><th>Study type</th><td>Interventional</td></tr><tr><th>Study design</th><td>Treatment</td></tr><tr><th>Study design</th><td>Double Blind</td></tr><tr><del style="background:#ffe6e6;"></del><th><del style="background:#ffe6e6">Study design</del></th><del style="background:#ffe6e6"></del><td><del style="background:#ffe6e6">Placebo Control</del></td><del style="background:#ffe6e6"></del></tr><del style="background:#ffe6e6"></del><tr><del style="background:#ffe6e6"></del><span></span><th>Primary outcome</th><td>Measure: <del style="background:#ffe6e6;"> </del><span>Behavioral, subjective, measures of naloxone-preci</span><del style="background:#ffe6e6;"> </del><span></span></td></tr><tr><th>Primary outcome</th><td>Measure: <del style="background:#ffe6e6;"> </del><span>Phsyiological, neuroendocrine measures of naloxone</span><del style="background:#ffe6e6;"> </del><span></span></td></tr><tr><th>Condition</th><td>         Opioid-Related Disorders      </td></tr><tr><th>Intervention</th><td><div>Drug: Gamma hydroxybutyric</div><ins style="background:#e6ffe6;"><p></p></ins><span></span></td></tr><tr><th>Reference</th><td><div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div><div>MEDLINE: </div></td></tr><tr><th class="section" colspan="2"><h2>Recruitment Information</h2></th></tr><tr><th>Status</th><td><del style="background:#ffe6e6;">            Completed         </del><ins style="background:#e6ffe6;">Withdrawn</ins><span></span></td></tr><tr><th>Start date</th><td>         199<del style="background:#ffe6e6;">6</del><ins style="background:#e6ffe6;">3</ins><span>-01      </span></td></tr><tr><th>Last <del style="background:#ffe6e6;">data entry</del><ins style="background:#e6ffe6;">follow-up date</ins></th><td>         1998-01            (Actual)  </td></tr><tr><th>Primary completion<span> date</span></th><td>         199<del style="background:#ffe6e6;">6-10</del><ins style="background:#e6ffe6;">8-01</ins><span> </span><ins style="background:#e6ffe6;">      (Actual)  </ins><span></span></td></tr><tr><th>Criteria</th></tr><tr><td class="bigdent" colspan="2"><p>Please contact site for information.</p></td></tr><tr><th>Gender</th><td>            Male         </td></tr><tr><th><del style="background:#ffe6e6;">Minimum age</del></th><del style="background:#ffe6e6"></del><td><del style="background:#ffe6e6">N/A</del></td><del style="background:#ffe6e6"></del></tr><del style="background:#ffe6e6"></del><tr><del style="background:#ffe6e6"></del><th><del style="background:#ffe6e6">Maximum age</del></th><del style="background:#ffe6e6"></del><td><del style="background:#ffe6e6">N/A</del></td><del style="background:#ffe6e6"></del></tr><del style="background:#ffe6e6"></del><tr><del style="background:#ffe6e6"></del><th><del style="background:#ffe6e6">Healthy volunteers</del></th><del style="background:#ffe6e6"></del><td><del style="background:#ffe6e6">No</del></td><del style="background:#ffe6e6"></del></tr><del style="background:#ffe6e6"></del><tr><del style="background:#ffe6e6"></del><th><del style="background:#ffe6e6">Expected enrollment</del></th><del style="background:#ffe6e6"></del><td><del style="background:#ffe6e6">0</del><ins style="background:#e6ffe6;">Healthy volunteers<td>No<span></span></td></ins></td></tr><tr><th class="section" colspan="2"><h2>Administrative Data</h2></th></tr><tr><th>Organization name</th><td><del style="background:#ffe6e6;">National Institute on Drug Abuse (NIDA)</del><ins style="background:#e6ffe6;">Yale University</ins><span></span></td></tr><tr><th>Organization study ID</th><td>NIDA-00191-2</td></tr><tr><th>Secondary ID</th><td><ins style="background:#e6ffe6;">K20DA000191      (US NIH Grant Number)    </ins></td></tr><tr><th>Secondary ID</th><td><span></span><del style="background:#ffe6e6;"> </del><span> </span><ins style="background:#e6ffe6;"> </ins><span>K20-00191-2         </span></td></tr><tr><th>Sponsor</th><td><ins style="background:#e6ffe6;">               Yale University            </ins></td></tr><tr><th>Collaborator</th><td><span>               National Institute on Drug Abuse (NIDA)            </span></td></tr><tr><th>Collaborator</th><td>               Yale University            </td></tr><tr><th>Health Authority</th><td>               United States: Federal Government         </td></tr></table></span></body></html></div></body>